Antithrombin: Global Strategic Business Report

Global Antithrombin Market to Reach $809.2 Million by 2030

The global market for Antithrombin estimated at US$538.8 Million in the year 2022, is projected to reach a revised size of US$809.2 Million by 2030, growing at a CAGR of 5.2% over the analysis period 2022-2030. Therapeutics, one of the segments analyzed in the report, is projected to record 5.3% CAGR and reach US$762.7 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Research segment is readjusted to a revised 3.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $161.7 Million, While China is Forecast to Grow at 4.9% CAGR

The Antithrombin market in the U.S. is estimated at US$161.7 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$142.2 Million by the year 2030 trailing a CAGR of 4.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 4.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5% CAGR.

Select Competitors (Total 41 Featured) -

• CSL Behring
• Grifols International SA
• Kedrion SpA
• Lee Biosolutions, Inc.
• LFB SA
• Scripps Laboratories
• Shire PLC

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and the publisher's Research Platform
• Complimentary updates for one year